***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: Hyperbaric oxygen therapy ( HOT ) is a safe and highly effective modality in the treatment of slow-healing wounds . It has been successfully employed in a variety of clinical conditions including nonhealing diabetic ulcers , chronic osteomyelitis , necrotizing fascitis , compartment syndromes , crush injuries and acute traumatic peripheral ischemia [ 1,2 ] . HOT has proven highly effective in the treatment of radiation-induced hemorrhagic cystitis , optic neuritis , decompression sickness , air embolism and CO intoxication [ 3,4 ] . Percutaneous coronary interventions ( PCIs ) invariably create miniature wounds by the disruptive effects of the interventional hardware on the vessel wall , thereby triggering the humoro-cellular responses leading to restenosis . Restenosis accounts for nearly 150,000 PCIs performed annually in this country alone , placing a significant toll on health care re sources . It st and s to reason to postulate that early healing of these miniature wounds by HOT can decrease restenosis . In an ongoing r and omized trial , we embarked to investigate the effect of  HOT  on restenosis . Our preliminary results have been encouraging [ 5,6 ] . The following constitutes our interim comparative findings In a previous pilot study , we demonstrated that adjunctive treatment with hyperbaric oxygen ( HBO ) appears to be feasible and safe in patients with acute myocardial infa rct ion ( AMI ) and may result in an attenuated rise in creatine phosphokinase ( CPK ) , more rapid resolution of pain and ST changes . This r and omized multicenter trial was organized to further assess the safety and feasibility of this treatment in human subjects . Patients with an AMI treated with recombinant tissue plasminogen activator ( rTPA ) or streptokinase ( STK ) , were r and omized to treatment with HBO combined with either rTPA or STK , or rTPA or STK alone .  An analysis included 112 patients , 66 of whom had inferior AMIs ( p = NS ) . The remainder of the patients had anterior AMIs . The mean CPK at 12 and 24 h was reduced in the HBO patients by approximately 7.5 % ( p = NS ) . Time to pain relief was shorter in the HBO group . There were 2 deaths in the control and 1 in those treated with HBO . The left ventricle ejection fraction ( LVEF ) on discharge was 51.7 % in the HBO group as compared to 48.4 % in the controls ( p = NS ) . The LVEF of the controls was 43.4 as compared to 47.6 for those treated , approximately 10 % better ( no significant difference ) . Treatment with HBO in combination with thrombolysis appears to be feasible and safe for patients with AMI and may result in an attenuated CPK rise , more rapid resolution of pain and improved ejection fractions . More studies are needed to assess the benefits of this treatment A r and omized , controlled clinical trial was carried out to study the effect of hyperbaric oxygen ( HBO ) on mortality  following recent acute myocardial infa rct ion in patients aged under 70 . One hundred and three patients were treated with HBO  and are compared with 105 controls treated conventionally in the same coronary care unit . Seventeen of the patients treated with HBO  died ( 16.5 per cent ) compared with 24 ( 22.9 per cent ) of the controls . When allowance is made by means of the Peel Index for the distribution of severely ill patients in the two groups this difference may be shown to be statistically significant at the 5 per cent level . The over-all mortality among the 80 patients who were exposed to a minimum of four hours in HBO was 11.3 per cent . Detailed analysis suggests that mortality in high-risk groups may be reduced by HBO to about a half . The only three patients with cardiogenic shock to survive were in the HBO group and the effect of the therapy in certain disorders of conduction is described . The advantages and disadvantages of HBO therapy are discussed . It is concluded that the evidence in favour of HBO treatment is sufficiently strong to justify its use in selected patients where facilities already exist and to warrant a more extensive trial BACKGROUND It has been shown that transient increase in left ventricular stiffness , assessed by Doppler-derived early filling deceleration time , occurs during the first 24 to 48 hours after myocardial infa rct ion but returns to normal within several days . It has been reported that hyperbaric oxygen treatment has a favorable effect on left ventricular systolic function in patients with acute myocardial infa rct ion treated with thrombolysis . However , there are no data on the effects of hyperbaric oxygen on diastolic function after myocardial infa rct ion . METHODS To assess acute and short-term effects of hyperbaric oxygen on left ventricular chamber stiffness , we studied 74 consecutive patients with first acute myocardial infa rct ion who were r and omly assigned to treatment with hyperbaric oxygen combined with streptokinase or streptokinase alone .  After thrombolysis , patients in the hyperbaric oxygen group received 100 % oxygen at 2 atm for 60 minutes in a hyperbaric chamber . All patients underwent 2-dimensional and Doppler echocardiography 1 ( after thrombolysis ) , 2 , 3 , 7 , 21 , and 42 days after myocardial infa rct ion . RESULTS Patient characteristics , including age , sex , risk factors , adjunctive postinfa rct ion therapy , infa rct location , and baseline left ventricular volumes and ejection fraction , were similar between groups ( P > .05 for all ) . For both groups , deceleration time decreased nonsignificantly from day 1 to day 3 and increased on day 7 ( P < .001 , for both groups ) , increasing nonsignificantly subsequently . The E/A ratio increased in the entire study group throughout the time of study ( P < .001 , for both groups ) . The pattern of changes of deceleration time was similar in both groups ( P > .05 by analysis of variance ) , as was in subgroups determined by early reperfusion success . CONCLUSIONS These data in a small clinical trial do not support a benefit of hyperbaric oxygen on left ventricular diastolic filling in patients with acute myocardial infa rct ion treated with thrombolysis BACKGROUND The role of hyperbaric oxygen in patients with acute myocardial infa rct ion is controversial , ranging from not beneficial to having a favorable effect . This r and omized study was conducted to further assess the benefit of hyperbaric oxygen treatment after thrombolysis on left ventricular function and remodeling in patients with acute myocardial infa rct ion . METHODS Seventy-four consecutive patients with first acute myocardial infa rct ion were r and omly assigned to treatment with hyperbaric oxygen treatment combined with streptokinase ( HBO+ ) or streptokinase alone ( HBO- ) . RESULTS There was a significant decrease of end-systolic volume index from the first day to the third week in HBO+ patients compared with HBO- patients ( from 30.40 to 28.18 vs from 30.89 to 36.68 mL/m2 , P < .05 ) accompanied with no changes of end-diastolic volume index in HBO+ compared with increased values in HBO- ( from 55.68 to 55.10 vs from 55.87 to 63.82 mL/m2 , P < .05 ) . Ejection fraction significantly improved in the HBO+ group and decreased in the HBO- group of patients after 3 weeks of acute myocardial infa rct ion ( from 46.27 % to 50.81 % vs from 45.54 % to 44.05 % , P < .05 ) . CONCLUSIONS Adjunctive hyperbaric oxygen therapy after thrombolysis in acute myocardial infa rct ion has a favorable effect on left ventricular systolic function and the remodeling process The purpose of this trial was to assess whether the addition of hyperbaric oxygen to percutaneous coronary intervention can reduce clinical restenosis . Major adverse cardiac events at 8 months were found in only 1 of 24 patients ( 4 % ) who received hyperbaric oxygen compared with 13 of 37 patients ( 35 % ) who did not To evaluate the potential for hyperbaric oxygen ( HBO ) to produce transient improvement in function in areas of myocardium ischemic at rest ( hibernating myocardium ) , 24 patients were studied within 1 week of acute myocardial infa rct ion . Results were compared with single-photon emission computed tomography ( SPECT ) thallium-201 exercise scintigraphy . Echocardiography demonstrated improved contraction following HBO in 20 of 62 damaged left ventricular segments in 12 of 24 patients . Thirteen of the 28 segments and 9 of the 14 patients showing reversible ischemia on SPECT imaging showed improvement with HBO . There were eight segments with apparently normal resting contraction that showed a reversible thallium defect . Of 42 segments with fixed contraction abnormalities following HBO , eight had reversible thallium defects , four had normal thallium kinetics , and 30 had fixed thallium defects . Thus hyperbaric oxygen can demonstrate improvement in function in some segments of left ventricle after infa rct ion . There is some overlap with viability as determined by thallium studies , but the two techniques may be complementary in describing myocardial ischemia Hyperbaric oxygen treatment ( HBO ) in combination with thrombolysis has been demonstrated to salvage myocardium in acute myocardial infa rct ion in the animal model . Therefore a r and omized pilot trial was undertaken to assess the safety and feasibility of this treatment in human beings . Patients with an acute myocardial infa rct ion ( AMI ) who received recombinant tissue plasminogen activator ( rTPA ) were r and omized to treatment with HBO  combined with  rTPA or rTPA alone . Sixty-six patients were included for analysis . Forty-three patients had inferior AMIs ( difference not significant ) and the remainder had anterior AMIs . The mean creatine phosphokinase level at 12 and 24 hours was reduced in the patients given HBO by approximately 35 % ( p = 0.03 ) . Time to pain relief and ST segment resolution was shorter in the group given HBO . There were two deaths in the control group and none in those treated with HBO . The ejection fraction on discharge was 52.4 % in the group given HBO compared with 47.3 % in the control group ( difference not significant ) . Adjunctive treatment with HBO appears to be a feasible and safe treatment for AMI and may result in an attenuated rise in creatine phosphokinase levels and more rapid resolution of pain and ST segment changes 
    Output:
    
For people with ACS , individual small trials suggest the addition of HBOT reduced the risk of Major Adverse Cardiac Events , some dysrrhythmias , and reduced the time to relief from ischaemic pain , but did not reduce mortality .